John J. Brems
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John J. Brems has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ryan M. Thomas
Department of Surgery, University of Florida College of Medicine, Gainesville, USA
3 shared publications Adam Riker
Loyola University Medical Center, 2160 S. First Ave., Building 110, Room 3268, Maywood, IL 60153, USA
1 shared publicationDavid H. Van Thiel
Department of Medicine, the Stritch School of Medicine, Loyola University of Chicago, Loyola University Medical Center, Maywood, IL
1 shared publicationDavid Holt
Department of Surgery, Loyola University Medical Center, Loyola University Stritch School of Medicine, Chicago, IL 60153, USA
1 shared publicationDavid Van Thiel
1 shared publicationDeborah Marra
Loyola University Medical Center, 2160 S. First Ave., Building 110, Room 3268, Maywood, IL 60153, USA
1 shared publication
Latest Publications
- 1 February 2011
- Published by American Medical Association (AMA)
- Vol. 146 (2) , 174
Assessing disease severity in patients with cholelithiasis.
- 1 February 2011
- Published by American Medical Association (AMA)
- Vol. 146 (2) , 174
Assessing disease severity in patients with cholelithiasis.
- 1 September 2003
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 9 (9) , 905-915
Infection with chronic hepatitis C virus and liver transplantation: A role for interferon therapy before transplantation
An analysis of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplant Registry data shows that the greater the viral load at the time of transplantation, the more rapidly clinically evident posttransplantation hepatitis C virus (HCV) disease recurs. These data suggest that aggressive pretransplantation treatment of HCV might delay recurrent posttransplantation HCV disease and enhance posttransplantation survival. We have taken an aggressive approach to treating HCV infection pretransplantation with the use of high-dose (5 MU) daily interferon α2b in an effort to clear the virus before transplantation. A total of 27 patients with HCV-induced cirrhosis were seen and underwent transplantation at Loyola University Medical Center (Maywood, IL) between February 1997 and December 2001. There were 22 men and five women, with a mean age of 56 ± 2 years. The majority had genotype 1 disease (67%). Of the 27 patients, 7 had a baseline platelet count 3 and were excluded from interferon therapy. The remaining 20 were treated for a mean of 14 ± 2.5 (range, 0.5 to 33.5) months before orthotopic liver transplantation (OLT). Twelve (60%) responded to the therapy with serologic clearance of HCV before OLT. The mean time from initiation of therapy to the first negative qualitative polymerase chain reaction was 4.5 ± 1.5 (range, 0.5 to 12) months. Four of the 12 patients in whom the virus cleared did not have evidence of HCV recurrence after OLT, representing 20% of those treated and 33% of those who had HCV clearance before OLT. The duration of post-OLT freedom from HCV infection in these individuals has been 33.6 ± 11.3 (range, 0 to 47.4) months. These data suggest that with careful supervision, cirrhotic patients can tolerate high-dose interferon. In addition, a viral clearance can be achieved in a significant number of cirrhotic patients with high-dose interferon. One third of patients, in whom the HCV cleared before OLT, did not have evidence of disease recurrence after OLT. It is thus anticipated that with early and aggressive pre-OLT HCV therapy, possibly with the use of pegylated interferon, even better results may be obtained.
- 1 September 2003
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 9 (9) , 905-915
Infection with chronic hepatitis C virus and liver transplantation: A role for interferon therapy before transplantation
An analysis of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplant Registry data shows that the greater the viral load at the time of transplantation, the more rapidly clinically evident posttransplantation hepatitis C virus (HCV) disease recurs. These data suggest that aggressive pretransplantation treatment of HCV might delay recurrent posttransplantation HCV disease and enhance posttransplantation survival. We have taken an aggressive approach to treating HCV infection pretransplantation with the use of high-dose (5 MU) daily interferon α2b in an effort to clear the virus before transplantation. A total of 27 patients with HCV-induced cirrhosis were seen and underwent transplantation at Loyola University Medical Center (Maywood, IL) between February 1997 and December 2001. There were 22 men and five women, with a mean age of 56 ± 2 years. The majority had genotype 1 disease (67%). Of the 27 patients, 7 had a baseline platelet count 3 and were excluded from interferon therapy. The remaining 20 were treated for a mean of 14 ± 2.5 (range, 0.5 to 33.5) months before orthotopic liver transplantation (OLT). Twelve (60%) responded to the therapy with serologic clearance of HCV before OLT. The mean time from initiation of therapy to the first negative qualitative polymerase chain reaction was 4.5 ± 1.5 (range, 0.5 to 12) months. Four of the 12 patients in whom the virus cleared did not have evidence of HCV recurrence after OLT, representing 20% of those treated and 33% of those who had HCV clearance before OLT. The duration of post-OLT freedom from HCV infection in these individuals has been 33.6 ± 11.3 (range, 0 to 47.4) months. These data suggest that with careful supervision, cirrhotic patients can tolerate high-dose interferon. In addition, a viral clearance can be achieved in a significant number of cirrhotic patients with high-dose interferon. One third of patients, in whom the HCV cleared before OLT, did not have evidence of disease recurrence after OLT. It is thus anticipated that with early and aggressive pre-OLT HCV therapy, possibly with the use of pegylated interferon, even better results may be obtained.
- 1 December 2002
- Published by Elsevier in The American Journal of Surgery
- Vol. 184 (6) , 611-615
Open Roux-en-Y gastric bypass for the morbidly obese in the era of laparoscopy
- 1 December 2002
- Published by Elsevier in The American Journal of Surgery
- Vol. 184 (6) , 611-615
Open Roux-en-Y gastric bypass for the morbidly obese in the era of laparoscopy
- Open Access
- 1 May 2002
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 137 (5) , 572-576
Use of Hepatitis B Core Antibody-Positive Donors in Orthotopic Liver Transplantation
THE INITIAL orthotopic liver transplantation (OLT) experience for patients with hepatitis B virus (HBV)-induced liver failure was dismal.1,2 These patients often developed recurrent HBV infection after transplantation, resulting in subsequent liver failure and death. Therefore, HBV infection became a contraindication for liver transplantation. This poor initial experience subsequently improved with the use of immunoprophylaxis, namely, hepatitis B immune globulin (HBIG). This therapy resulted in outcomes for this population comparable to those of patients who underwent transplantation for non-HBV disease. Another drug, lamivudine, has also been shown to be effective in eradicating HBV viremia and has been used as additional prophylaxis for HBV-infected patients undergoing OLT.
- 1 May 2002
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 137 (5) , 572-576
Open AccessUse of Hepatitis B Core Antibody-Positive Donors in Orthotopic Liver Transplantation
THE INITIAL orthotopic liver transplantation (OLT) experience for patients with hepatitis B virus (HBV)-induced liver failure was dismal.1,2 These patients often developed recurrent HBV infection after transplantation, resulting in subsequent liver failure and death. Therefore, HBV infection became a contraindication for liver transplantation. This poor initial experience subsequently improved with the use of immunoprophylaxis, namely, hepatitis B immune globulin (HBIG). This therapy resulted in outcomes for this population comparable to those of patients who underwent transplantation for non-HBV disease. Another drug, lamivudine, has also been shown to be effective in eradicating HBV viremia and has been used as additional prophylaxis for HBV-infected patients undergoing OLT.